For more than seven years, Dr. Erol Onel from Scarsdale, New York, oversaw the pain and oncology divisions, providing medical oversight at Pacira Pharmaceuticals, Inc., in La Jolla, CA. His responsibilities as vice president of clinical research and medical information included launching a new drug called bupivacaine liposome injectable suspension and training healthcare professionals on its capabilities and administration. Dr. Erol Onel coauthored multiple articles on the drug, including one that appeared in the February 2014 printing of the Clinical Journal of Pain.
Dr. Erol Onel graduated from the Albert Einstein College of Medicine, and he later fulfilled professorships at Tufts University and the Andover Urology Lahey Clinic. He entered the pharmaceutical industry in 2004 as a senior associate director at Boehringer Ingelheim Pharmaceuticals in Ridgefield, Connecticut.
Class of 1992
BA, Philosophy and Biology/Science and Technology Studies, 1984 – 1988
American Urological Association – AUA
American Medical Association – AMA
American Society of Reproductive Medicine – ASRM
The safety of liposome bupivacaine, a novel local analgesic formulation.
Clin J Pain
Viscusi ER, Sinatra R, Onel E, Ramamoorthy SL
Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site.
Clin Drug Investig
Hu D, Onel E, Singla N, Kramer WG, Hadzic A
A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty.
Bramlett K, Onel E, Viscusi ER, Jones K